Drug Profile

HRS 4357

Alternative Names: HRS-4357

Latest Information Update: 06 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 Dec 2025 Jiangsu HengRui Medicine Co. plans a phase III trial for the treatment of Prostate Cancer (Metastatic, Hormone refractory, Second-line therapy or greater, Late-stage disease) in China (Parenteral, injection), in January 2026 (NCT07311694)
30 Sep 2023 Phase-I/II clinical trials in Prostate cancer (Late-stage disease) (Parenteral) (NCT06006104)
28 Aug 2023 Preclinical trials in Prostate cancer in China (Parenteral), prior to August 2023 (Jiangsu HengRui Medicine pipeline, August 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com